[Nabiximols for spasticity and chronic pain]
Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001449
Spanish
Original Title:
Nabiximols para espasticidad y dolor crónico
Authors' recommendations:
CONCLUSIONS
Low-quality evidence does not allow determining if nabiximols has a clinically significant benefit in spasticity and chronic pain.
This drug has not been approved by ANMAT (Argentina’s National Administration of Drugs, Foods and Medical Devices) and is imported for compassionate use. Some clinical practice guidelines suggest it might be an option as second-line or subsequent therapy drug for multiple sclerosis spasticity and management of neuropathic pain of central nervous system origin. Most of the international public sponsors consulted do no cover this technology. Those who do cover it, have a previous funding agreement with the industry.
No economic evaluations assessing cost-effectiveness at local level have been found.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Chronic Pain
- Muscle Spasticity
- Cannabidiol
- Medical Marijuana
- Multiple Sclerosis
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.